Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $103.5 million versus the consensus estimate of $102.3 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.